Mortality from bone marrow suppression after chemotherapy

Bone marrow suppression is a common side effect of chemotherapy, and the mortality rate is actually relatively low.

Bone marrow suppression refers to the effect of chemotherapy drugs on bone marrow hematopoietic function, resulting in a decrease in blood cell count, which may lead to anemia, infection, bleeding and other complications. Fortunately, with the advancement of medical technology, there are more and more drugs and methods for treating bone marrow suppression, such as leukocyte-raising drugs, platelet-raising drugs, etc., which can effectively relieve the symptoms of bone marrow suppression.

Of course, the severity of bone marrow suppression and the patient's physical condition also affect the mortality rate. The risk of severe myelosuppression and mortality may increase in patients with poor constitution, repeated chemotherapy, or high-intensity chemotherapy regimens, but overall, most patients survive myelosuppression if identified and treated effectively.

Therefore, mortality from myelosuppression should not be an excessive concern for patients receiving chemotherapy. It is important to actively cooperate with the doctor's treatment plan, regularly review blood routine and other indicators, and timely discover and deal with adverse reactions such as bone marrow suppression.